TON Web Exclusives

At 10-year follow-up, investigators observed similar outcomes with exemestane alone and sequential tamoxifen/exemestane in the phase 3 TEAM trial of postmenopausal women with hormone receptor (HR)-positive early breast cancer.
The results of a recent gene-sequencing analysis identify new pathogenic mutations associated with an increased risk for breast cancer.
The extended use of anastrozole for 3 years beyond 5 years of sequential therapy did not improve disease-free survival or overall survival in postmenopausal women with hormone receptor–positive, early breast cancer.
The addition of carboplatin increases response in patients with triple-negative breast cancer without pathogenic BRCA1 and BRCA2 mutations.
Prolonged use of hormonal contraceptives slightly increases the risk for breast cancer.
Intraventricular HER2 CAR T-cell therapy may be an option for patients with HER2+ breast cancer and brain metastasis.
In the phase 3 OlympiAD trial, treatment with olaparib significantly improved progression-free survival and reduced the risk for disease progression or death compared with standard chemotherapy in women with HER2-negative, BRCA-mutated metastatic breast cancer.
PD-L1 positivity in all cells in patients with breast cancer may be a useful prognostic marker based on a recent meta-analysis.
A new analysis shows that there is an ongoing, steady risk for metastatic or distant recurrence of cancer from years 5 to 20 among women with estrogen receptor–positive breast cancer.
After accounting for the benefit of pertuzumab, investigators found that >6 cycles of docetaxel did not significantly improve progression-free or overall survival in patients with HER2-positive, metastatic breast cancer.
Page 1 of 4
Results 1 - 10 of 36